Pulse cyclophosphamide in ocular manifestations of Behcet's disease: A double blind controlled crossover study

Archives of Iranian Medicine

Volumn 7, Issue 3, 2004, Pages 201-205

  Davatchi, Fereydoun ^a,b   Shahram, Farhad ^a   Chams, Hormoz ^a   Akbarian, Mahmood ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Behcet's disease; Ocular lesions; Pulse cyclophosphamide

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO; PREDNISOLONE;

ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PULSE THERAPY; EYE DISEASE; HUMAN; RANDOMIZED CONTROLLED TRIAL; RETINA VASCULITIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UVEITIS; VISUAL ACUITY;

EID: 7944238127     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Davatchi F, Shahram F, Akbarian M, et al. Behcet's disease. Analysis of 3,443 cases. APLAR J Rheumatol. 1997; 1: 2-5.
2. Davatchi F, Shahram F, Chams C, et al. Nonocular manifestations of Behcet's disease. In: Zierhut M, Ohno S, eds. Immunology of Behcet's Disease. 5th ed. Lisse: Swets and Zeitlinger B.V.; 2003: 21-35.
3. Davatchi F. Behcet's disease. In: Howe HS, Feng PH, eds. Textbook of Clinical Rheumatology. Singapore: National Arthritis Foundation; 1998: 298-315.
4. Davatchi F. Treatment of ocular manifestations of Behcet's disease. Adv Exp Med Biol. 2003; 528: 487-491.
5. Davatchi F, Shahram F, Chams H, et al. Pulse cyclophosphamide in ophthalmological manifestations of Behcet's disease. In: O'Duffy JD, Kokmen E, eds. Behcet's Disease Basic and Clinical Aspects. New York: Marcel Decker; 1991: 555-561.
6. Davatchi F, Shahram F, Chams H, et al. Pulse cyclophosphamide for ocular manifestations of Behcet's disease. Cohort study on 283 patients. Rev Rheum (Engl Ed). 1998; 65: 692.
7. Shahram F, Davatchi F, Chams H, Akbarian M, Gharibdoost F. Low-dose pulse cyclophosphamide (LDP) in ophthalmologic lesions of Behcet's disease. In: Godeau P, Wechsler B, eds. Behcet's Disease. Amsterdam: Elsevier Science Publishers B.V.; 1993: 683-686.
8. Shahram F, Davatchi F, Chams H, Akbarian M, Chams C. Pulse cyclophosphamide versus pulse methotrexate in ophthalmological manifestations of Behcet's disease. In: Nasution AR, Darmawan J, Isbagio H, eds. APLAR Rheumatology 1992. Tokyo: Churchill Livingstone; 1992: 119-122.
9. Shahram F, Davatchi F, Chams H, Akbarian M, Chams C, Tebbi ME. Methotrexate in ocular Behcet's disease. Preliminary report. First APLAR Symposium on the Therapy of Rheumatic Diseases; November 1990. Seoul, Korea; Abstract FP - 23.
10. Davatchi F, Shahram F, Chams H, et al. Methotrexate for ocular lesions of Behcet's disease. Cohort study on 262 patients. Arthritis Rheum. 1998; 41: S356.
11. Shahram F, Davatchi F, Chams H, Akbarian M, Gharibdoost F. Comparing 3 methods of cytotoxic therapy in ophthalmologic lesions of Behcet's disease. In: Godeau P, Wechsler B, eds. Behcet's Disease. Amsterdam: Elsevier Science Publishers B.V.; 1993: 635-640.
12. Shahram F, Davatchi F, Chams H, Akbarian M. Cyclosporin in severe ocular lesions of Behcet's disease. In: Harnza M, ed. Behcet's Disease. Tunis: Pub Adhoua; 1997: 421-423.
13. Davatchi F, Shahram F, Chams H, et al. Azathioprine for the treatment of ophthalmologic lesions of Behcet's disease. In: Bang D, Lee ES, Lee S, eds. Behcet's Disease. Seoul: Design Mecca Publishing; 2000: 898-900.
14. Davatchi F, Shahram F, Gharibdoost F, et al. Outcome analysis of ocular lesions in Behcet's disease with 6 different therapeutic methods. Arthritis Rheum. 1996; 39: S217.
15. Davatchi F. Neuroophthalmic Behcet's. In: Torralba TP, Amante CM, Victorio-Navarra STG, eds. APLAR JRD Symposium on the Therapy of Rheumatic Diseases 1998. Hong Kong: Excerpta Medica Asia; 1997: 16-17.
16. Davatchi F, Shahram F, Chams H, et al. High-dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv Exp Med Biol. 2003; 528: 579-584.
17. Shahram F, Davatchi F, Chams H, et al. Azathioprine and low-dose pulse cyclophosphamide in severe ocular lesions of Behcet's disease. A preliminary report. Adv Exp Med Biol. 2003; 528: 571-573.
18. Davatchi F, Shahram F, Chams H, et al. The influence of the delay of aggressive treatment on the vision and its outcome in Behcet's disease. Adv Exp Med Biol. 2003; 528: 493-494.
19. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's disease: effects on long-term prognosis. Arthritis Rheum. 1997; 40: 769-774.
20. Davatchi F, Shahram F, Akbarian M, et al. Classification tree for the diagnosis of Behcet's disease. In: Godeau P, Wechsler B, eds. Behcet's Disease. Amsterdam: Elsevier Science Publishers B.V.; 1993: 245-248.
21. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990; 335: 1078-1080.
22. Senn SJ. Crossover Trials in Clinical Research. New York: John Wiley and Sons; 1993.
23. Ben Ezra D, Cohen E. Treatment in ocular Behcet's disease. In: O'Duffy JD, Kokmen E, eds. Behcet's Disease: Basic and Clinical Aspects. New York: Marcel Decker; 1991: 619-623.